{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:01Z","timestamp":1793640721667,"version":"4.5.1"},"reference-count":12,"publisher":null,"issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/cardio.elpub.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>\n                    <jats:italic>Aim:<\/jats:italic>\n                    To evaluate the effect of inclisiran therapy on the blood lipid profile 90 days post-injection and to describe the baseline structural and ultrasound characteristics of carotid and femoral plaques in high- and very high-risk patients who failed to achieve low-density lipoprotein cholesterol goals despite ongoing lipid-lowering treatment.\n                    <jats:italic>Material and methods:<\/jats:italic>\n                    This prospective observational single-center study included 22 patients (mean age 50.9\u00b18.6 years, 50% men) with dyslipidemia and atherosclerotic plaques in peripheral arteries narrowing the lumen by 25-49%. Familial hypercholesterolemia was diagnosed in 59% of patients, and statin intolerance in 36%. Duplex scanning of the carotid and femoral arteries was performed. The gray-scale median (GSM) method is currently used for the quantitative assessment of carotid artery (CA) plaque echogenicity. Inclisiran was administered on day 1, day 90, and then every six months. Blood lipid profiles, including low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglycerides, and lipoprotein (a) [Lp(a)], were assessed.\n                    <jats:italic>Results:<\/jats:italic>\n                    At baseline, median concentrations were 3.7 [2.5; 5.4] mmol\/l for LDL-C, 5.4 [4.4; 6.8] mmol\/l for TC, and 22.0 [5.0; 108.0] mg\/dl for Lp(a). Carotid artery evaluation showed a median of 4.0 [2.0; 4.0] plaques, total stenosis of 110% [63.8; 118.8], and a GSM of 38.6 [28.6; 52.4], with a predominance of heterogeneous plaques (59%). Femoral artery assessment revealed a median of 2.0 [2.0; 3.0] plaques, 75% [42.5; 111.3] total stenosis, and a minimum echogenicity of 41.5 [33.4; 57.4] gray-scale units, with 65% heterogeneous plaques. Ninety days post-initiation of inclisiran, LDL-C was reduced by 65% (to 1.3 [1.2; 2.9] mmol\/L, p&lt;0.01), TC by 30% (p&lt;0.01), triglycerides by 35%, and Lp(a) by 33%.\n                    <jats:italic>Conclusion:<\/jats:italic>\n                    Inclisiran demonstrated high efficacy in reducing LDL-C levels in patients at high and very high risk of cardiovascular disease who failed to reach targets with standard therapy. The identified plaque characteristics indicate a high risk of atherothrombosis in this cohort. The dynamics of these structural plaque changes will be assessed after completing the one-year follow-up.\n                  <\/jats:p>","DOI":"10.18087\/cardio.2026.1.n3108","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:56:45Z","timestamp":1770821805000},"page":"46-54","source":"Crossref","is-referenced-by-count":0,"title":["Inclisiran Therapy and Lipid Profile Dynamics in Real-World Clinical Practice in Russia: Interim Results of an Observational Study"],"prefix":"10.68900","volume":"66","author":[{"given":"M. V.","family":"Ezhov","sequence":"first","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3505-2487","authenticated-orcid":true,"given":"A. V.","family":"Tyurina","sequence":"additional","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7897-4727","authenticated-orcid":true,"given":"O. A.","family":"Pogorelova","sequence":"additional","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3617-9343","authenticated-orcid":true,"given":"N. A.","family":"Tmoyan","sequence":"additional","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4462-3894","authenticated-orcid":true,"given":"M. I.","family":"Tripoten","sequence":"additional","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4500-0904","authenticated-orcid":true,"given":"N. V.","family":"Gomyranova","sequence":"additional","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7273-6979","authenticated-orcid":true,"given":"T. V.","family":"Balakhonova","sequence":"additional","affiliation":[{"name":"Chazov National Medical Research Center of Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Ignatyeva V.I., Ezhov M.V., Kontsevaya A.V., Paleev F.N., Derkach E.V., Omelianovsky V.V. et al. Socio-economic damage caused by elevated low-density lipoprotein cholesterol levels. Medical Technologies. Assessment and Choice. 2025;2(47):88\u201398. DOI: 10.17116\/medtech20254702188","DOI":"10.17116\/medtech20254702188"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Andersson NW, Corn G, Dohlmann TL, Melbye M, Wohlfahrt J, Lund M. LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals. Journal of the American College of Cardiology. 2023;82(14):1381\u201391. DOI: 10.1016\/j.jacc.2023.07.027","DOI":"10.1016\/j.jacc.2023.07.027"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ et al. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg\/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. Circulation. 2017;136(20):1878\u201391. DOI: 10.1161\/CIRCULATIONAHA.117.027966","DOI":"10.1161\/CIRCULATIONAHA.117.027966"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Kadoglou N, Moulakakis KG, Mantas G, Spathis A, Gkougkoudi E, Mylonas SN et al. Novel Biomarkers and Imaging Indices for the \u201cVulnerable Patient\u201d with Carotid Stenosis: A Single-Center Study. Biomolecules. 2023;13(9):1427. DOI: 10.3390\/biom13091427","DOI":"10.3390\/biom13091427"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Ruiz-Ares G, Fuentes B, Mart\u00ednez-S\u00e1nchez P, D\u00edez-Tejedor E. A Prediction Model for Unstable Carotid Atheromatous Plaque in Acute Ischemic Stroke Patients: Proposal and Internal Validation. Ultrasound in Medicine & Biology. 2014;40(9):1958\u201365. DOI: 10.1016\/j.ultrasmedbio.2014.04.015","DOI":"10.1016\/j.ultrasmedbio.2014.04.015"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Spanos K, Tzorbatzoglou I, Lazari P, Maras D, Giannoukas AD. Carotid artery plaque echomorphology and its association with histopathologic characteristics. Journal of Vascular Surgery. 2018;68(6):1772\u201380. DOI: 10.1016\/j.jvs.2018.01.068","DOI":"10.1016\/j.jvs.2018.01.068"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. New England Journal of Medicine. 2017;376(15):1430\u201340. DOI: 10.1056\/NEJMoa1615758","DOI":"10.1056\/NEJMoa1615758"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. New England Journal of Medicine. 2020;382(16):1507\u201319. DOI: 10.1056\/NEJMoa1912387","DOI":"10.1056\/NEJMoa1912387"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Iqbal S, Sabbour HM, Ashraf T, Santos RD, Buckley A. First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population. Clinical Therapeutics. 2024;46(3):186\u201393. DOI: 10.1016\/j.clinthera.2023.12.003","DOI":"10.1016\/j.clinthera.2023.12.003"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Landmesser U, Laufs U, Schatz U, Winzer EB, Nowak B, Kassner U et al. Inclisiran-based treatment strategy in hypercholesterolaemia: the VICTORION-difference trial. European Heart Journal. 2025;ehaf685. [Epub ahead of print]. DOI: 10.1093\/eurheartj\/ehaf685","DOI":"10.1093\/eurheartj\/ehaf685"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Katsiki N, Vrablik M, Banach M, Gouni-Berthold I. Inclisiran, LowDensity Lipoprotein Cholesterol and Lipoprotein (a). Pharmaceuticals. 2023;16(4):577. DOI: 10.3390\/ph16040577","DOI":"10.3390\/ph16040577"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. European Heart Journal. 2023;44(2):129\u201338. DOI: 10.1093\/eurheartj\/ehac594","DOI":"10.1093\/eurheartj\/ehac594"}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/viewFile\/3108\/1964","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:16:49Z","timestamp":1793639809000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/3108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,11]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2026.1.n3108","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}